Text Size

Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Piotr Kozlowski, University Hospital Orebro
ClinicalTrials.gov Identifier:
NCT01470924
First received: November 7, 2011
Last updated: November 10, 2011
Last verified: November 2011
History of Changes
  Purpose

A minority of patients with adult acute lymphoblastic leukemia (ALL) relapse are rescued. The aim of this population-based study was to assess the results of reinduction treatment and allogeneic stem cell transplantation (SCT) in second complete remission (CR) in Sweden 2003-2007.


Condition
Acute Lymphoblastic Leukemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: High Curability Via Intensive Reinduction Chemotherapy and Stem Cell Transplantation in Young Adults With Relapsed Acute Lymphoblastic Leukemia in Sweden 2003-2007

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University Hospital Orebro:

Enrollment: 76
Study Start Date: January 2003
Study Completion Date: June 2011
Detailed Description:

This is a national, multicenter, prospective, population-based study of outcome among adult patients aged 19 to 65 years with ALL relapse diagnosed during 2003-2007 in Sweden. Most of the patients had primary treatment according to National guidelines for ALL as recommended by The Swedish Adult ALL Group (SVALL). The guidelines suggest two different treatment protocols for early relapses, and retreatment according to the initial therapy for late relapses, with the intention to proceed to allogeneic SCT in CR2 for eligible patients. The aim of the current study was to assess outcome among adult patients after first ALL relapse, and the utilization and efficacy of recommended protocols and of allogeneic SCT in this setting.

  Eligibility

Ages Eligible for Study:   18 Years to 66 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All adults with relapsed ALL

Criteria

Inclusion Criteria:

  • Adult patients with first relapse of ALL

Exclusion Criteria:

  • patients with Burkitt leukemia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01470924

Locations
Sweden
Orebro University Hospital
Orebro, Orebro County, Sweden, 70185
Sponsors and Collaborators
University Hospital Orebro
Investigators
Principal Investigator: Piotr J Kozlowski, MD Orebro University Hospital
  More Information

No publications provided

Responsible Party: Piotr Kozlowski, Principal Investigator, University Hospital Orebro
ClinicalTrials.gov Identifier: NCT01470924     History of Changes
Other Study ID Numbers: OLL-180361
Study First Received: November 7, 2011
Last Updated: November 10, 2011
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by University Hospital Orebro:
acute lymphoblastic leukemia
relapse
salvage
prognostic

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Neoplasms
 Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on May 21, 2013